Read More Pharma Industry News Nuvalent’s neladalkib posts 44% response rate in ALK-positive solid tumors beyond lung cancer Discover how Nuvalent’s neladalkib delivered a 44% response rate in ALK-positive solid tumors beyond NSCLC and what this means for oncology. bySrinathOctober 19, 2025